Cargando…
Trastuzumab Modulates the Protein Cargo of Extracellular Vesicles Released by ERBB2(+) Breast Cancer Cells
Cancers overexpressing the ERBB2 oncogene are aggressive and associated with a poor prognosis. Trastuzumab is an ERBB2 specific recombinant antibody employed for the treatment of these diseases since it blocks ERBB2 signaling causing growth arrest and survival inhibition. While the effects of Trastu...
Autores principales: | Marconi, Silvia, Santamaria, Sara, Bartolucci, Martina, Stigliani, Sara, Aiello, Cinzia, Gagliani, Maria Cristina, Bellese, Grazia, Petretto, Andrea, Cortese, Katia, Castagnola, Patrizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000509/ https://www.ncbi.nlm.nih.gov/pubmed/33809102 http://dx.doi.org/10.3390/membranes11030199 |
Ejemplares similares
-
Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2(+) breast cancer cells
por: D’Alesio, Carolina, et al.
Publicado: (2017) -
Lipid Metabolism Reprogramming and Trastuzumab Resistance in Breast Cancer Cell Lines Overexpressing the ERBB2 Membrane Receptor
por: Cortese, Katia, et al.
Publicado: (2023) -
Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells
por: Castagnola, Patrizio, et al.
Publicado: (2016) -
The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2(+) breast cancer cells
por: D'Alesio, Carolina, et al.
Publicado: (2019) -
Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells
por: Bagnato, Paola, et al.
Publicado: (2017)